Xencor (NASDAQ:XNCR) Now Covered by Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald started coverage on shares of Xencor (NASDAQ:XNCR) in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm set an “overweight” rating and a $70.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s price objective would indicate a potential upside of 105.58% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Wedbush raised their target price on shares of Xencor from $30.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, October 27th. Truist Financial upped their price target on shares of Xencor from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, October 27th. Wall Street Zen upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Royal Bank Of Canada lifted their price objective on shares of Xencor from $20.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.22.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $34.05 on Thursday. The stock has a 50 day moving average price of $26.04 and a 200 day moving average price of $17.34. Xencor has a 52 week low of $10.38 and a 52 week high of $35.81.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.83. Xencor had a negative return on equity of 21.37% and a negative net margin of 58.79%. The firm had revenue of $116.52 million for the quarter, compared to analyst estimates of $63.00 million. During the same quarter in the previous year, the firm earned ($0.08) EPS. The business’s quarterly revenue was up 453.3% on a year-over-year basis. As a group, sell-side analysts predict that Xencor will post -3.05 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Xencor during the 2nd quarter worth about $219,785,000. Primecap Management Co. CA acquired a new position in Xencor in the 2nd quarter valued at about $163,919,000. Jefferies Financial Group Inc. raised its holdings in Xencor by 189.0% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,082,243 shares of the biopharmaceutical company’s stock valued at $51,952,000 after acquiring an additional 1,361,803 shares during the period. Dimensional Fund Advisors LP raised its holdings in Xencor by 3.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock valued at $15,613,000 after acquiring an additional 45,599 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Xencor during the second quarter worth approximately $17,568,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.